Seres Therapeutics News

Express News | Seres Therapeutics Concludes Enrollment In Cohort 2 Of Phase 1B Trial Of SER-155 In Allogeneic Hematopoietic Stem Cell Transplant Patients; Clinical Data Readout Expected End Of Q3 2024

Moomoo 24/7Apr 9 07:11 ET

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

PDF Version Clinical data readout expected end of Q3 2024 SER-155 and other Seres microbiome therapeutic candidates have potential to expand microbiome therapeutic franchise into additional medic

Seres TherapeuticsApr 9 00:00 ET

Increases to Seres Therapeutics, Inc.'s (NASDAQ:MCRB) CEO Compensation Might Cool off for Now

Yahoo FinanceMar 28 12:47 ET

Revenues Working Against Seres Therapeutics, Inc.'s (NASDAQ:MCRB) Share Price Following 27% Dive

To the annoyance of some shareholders, Seres Therapeutics, Inc. (NASDAQ:MCRB) shares are down a considerable 27% in the last month, which continues a horrid run for the company. The recent drop com

Simply Wall StMar 28 12:32 ET

Express News | Seres Therapeutics Announced That On March 25, 2024, The Compensation And Talent Committee Of Seres' Board Of Directors Granted Inducement Equity Grants Of 700,000 Shares To Marella Thorell, New Executive Vice President And CFO

Moomoo 24/7Mar 28 07:26 ET

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PDF Version CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 19, 2024-- Seres Therapeutics, Inc. (Nasdaq: MCRB) ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that

Seres TherapeuticsMar 19 00:00 ET

11 Oversold NASDAQ Stocks To Buy Right Now

Yahoo FinanceMar 13 15:32 ET

11 Oversold Healthcare Stocks To Buy Right Now

Yahoo FinanceMar 13 08:17 ET

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2023 Earnings Call Transcript

Yahoo FinanceMar 7 11:48 ET

Emerson Electric To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Morgan Sta

BenzingaMar 6 08:00 ET

Oppenheimer Sticks to Its Buy Rating for Seres Therapeutics (MCRB)

TipRanksMar 6 07:55 ET

Seres Therapeutics Is Maintained at Buy by Chardan Capital

Seres Therapeutics Is Maintained at Buy by Chardan Capital

Dow JonesMar 6 07:49 ET

Express News | Chardan Capital Maintains Buy on Seres Therapeutics, Lowers Price Target to $8

Moomoo 24/7Mar 6 07:38 ET

Q4 2023 Seres Therapeutics Inc Earnings Call

Yahoo FinanceMar 6 02:17 ET

A New Cause for Concern: Seres Therapeutics Inc. Adds a New Supply Chain Risk

TipRanksMar 6 01:01 ET

Seres Therapeutics (MCRB) Gets a Buy From TD Cowen

TipRanksMar 5 23:55 ET

Earnings Call Summary | Seres Therapeutics(MCRB.US) Q4 2023 Earnings Conference

The following is a summary of the Seres Therapeutics, Inc. (MCRB) Q4 2023 Earnings Call Transcript:Financial Performance:Seres Therapeutics and Nestle Health Science managed to exceed expectations wit

moomoo AIMar 5 15:52 ET · Conference Call

Seres Therapeutics Inc (MCRB) Reports Encouraging Sales Growth and Strategic Cost Savings in 2023

Yahoo FinanceMar 5 07:32 ET

Express News | Seres' $128M In Cash Balance, Planned Savings From Restructuring Announced In November 2023, And, Assuming Continued Revenue Growth Of Vowst, Expected Receipt Of The $45M Tranche B Under Its Secured Debt Will Support Its Operations Into Q4 2024

Moomoo 24/7Mar 5 07:07 ET

Seres Therapeutics GAAP EPS of -$0.89 Beats by $0.10, Revenue of $126.33M Beats by $0.23M

Seeking AlphaMar 5 07:03 ET